Company: HCTI
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001213900-25-045994
Chunk: 94

Company: Healthcare Triangle, Inc.
Filing Date: 2025-05-20
Form: 10-Q
Item: Part I, Item 8
Chunk 94
---
 of common stock outstanding during
the period for the effects of all dilutive potential common shares, including awards under stock-based compensation arrangements.

The Company’s unvested restricted stock
awards are considered participating securities under FASB Codification topic, Earnings Per Share, because they entitle holders
to non-forfeitable rights to dividends until the awards vest or are forfeited. When a company has a security that qualifies as a “participating
security,” the Codification requires the use of the two-class method when computing basic EPS. The two-class method is an earnings
allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated)
and participation rights in undistributed earnings. In determining the amount of net income to allocate to common stockholders, income
is allocated to both common stock and participating securities based on their respective weighted average shares outstanding for the period,
with net income attributable to common stockholders ultimately equally net income less net income attributable to participating securities.
Diluted EPS for the Company’s common stock is computed using the more dilutive of the two-class method or the treasury stock method.

Schedule of earning per share

    Three Months Ended March 31, 

    2025  
    2024 
  
    Net income attributable to common stockholders 
    $(1,700) 
    $(1,862)
  
    Weighted average shares outstanding – basic and diluted 
     9,843,821  
     4,455,245 
  
    Basic and diluted EPS 
     (0.17) 
     (0.42)

16) Subsequent Events

1. The Company received the notice of effectiveness of Form S-1 on
May 14, 2025.

2. The Company has issued 29,173,056 Common stocks to holders of the pre-funded
warrants.

3. The Company has issued 316,206,975 Common
stock to holders of Series B warrants on exercise of the “zero exercise price option”

26

Item 2. Management’s discussion and analysis
of financial condition and results of operations. 

The following discussion summarizes the significant
factors affecting the operating results, financial condition, liquidity, and cash flows of our Company as of and for the periods presented
below. The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and the
related notes thereto, and the consolidated financial statements and the related notes